Tagriso shown to slow spread of EGFR gene mutation brain metastases

Organisation: Position: Deadline Date: Location:

AstraZeneca’s top-selling drug Tagrisso has been shown to slow the spread of a certain type of lung cancer to the brain when diagnosed at an early stage, according to a study presented at the European Society for Medical Oncology conference. A study with patients diagnosed early enough for the lung tumour to be surgically removed, and who have a mutation of the so-called EGFR gene, found that Tagrisso cut the risk of developing brain metastases by 82%.

The late-stage Phase III trial results – presented at the virtual European Society for Medical Oncology (ESMO) conference – underscore the drug’s potential and may encourage a push to diagnose lung cancer earlier for patients to benefit from the drug, Astra said.

According to earlier findings of the same trial known as ADAURA, Tagrisso held back early-stage EGFR mutated lung cancer. Revenue from Tagrisso climbed 43% to $2bn in the first half of the year, mainly from EGFR-mutated lung cancer diagnosed when it has already spread to other body parts, driving sales growth in oncology.

The EGFR mutation is found in about a quarter of global lung cancer cases, but the rate in Asia can be more than 40%.

European Society for Medical Oncology (ESMO) conference abstract not yet available online

Full Reuters Health report

Receive Medical Brief's free weekly e-newsletter

Related Posts

Thank you for subscribing to MedicalBrief

MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.

Thank you for taking the time to complete the form.